GoAI
Get started
Lexicon Pharmaceuticals, Inc. logo

Lexicon Pharmaceuticals, Inc.

LXRX

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$2.30

+$0.12 · +5.50%

Aug 21, 4:00 PM ET

LXRX company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

75

Undervalued

Momentum

63

Gaining

Sentiment

55

Mixed

Risk resilience

47

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the end-to-end process of identifying, advancing, and bringing to market novel therapeutic compounds. Its development pipeline includes orally administered small molecule drug candidates such as Sotagliflozin, which has successfully concluded Phase III clinical studies for treating both heart failure and type 1 diabetes, and LX9211, currently undergoing Phase II clinical development for neuropathic pain. The firm maintains important strategic collaborations and licensing arrangements with pharmaceutical industry leaders, including Bristol-Myers Squibb Company and Genentech, Inc. Established in 1995, Lexicon Pharmaceuticals, Inc. is based in The Woodlands, Texas.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Michael S. Exton
Listed since
Apr 7, 2000
Employees
81

Market position

Day range

Current $2.30

52-week range

Current $2.30

Open
$2.20
Previous close
$2.18
Volume
3.19M
1.01× average
Average volume
3.15M
Average daily volume
Market cap
1.02B USD
Beta
1.04
Market reference 1
50-day average
$2.2814
+0.82% above average
200-day average
$1.7439
+31.89% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
445.42M USD
P/E (TTM)
-15.29×
P/B (TTM)
5.77×
P/S (TTM)
24.64×
EV / EBITDA
-10.76×
Earnings yield
-12.06%
Free cash flow yield
-16.25%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
98.85%
Operating margin
-131.43%
Net margin
-147.38%
Return on equity
-46.81%
Return on assets
-27.21%
Return on invested capital
-28.71%

Financial health

Debt / equity
0.34×
Current ratio
4.88×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends7443%-21933%-51309%-80685%Gross margin, FY2021: -18371.81%Gross margin, FY2022: -37681.29%Gross margin, FY2023: -4798.01%Gross margin, FY2024: 98.02%Gross margin, FY2025: 99.45%Operating margin, FY2021: -29224.83%Operating margin, FY2022: -72489.21%Operating margin, FY2023: -14264.95%Operating margin, FY2024: -634.20%Operating margin, FY2025: -98.21%Net margin, FY2021: -29448.99%Net margin, FY2022: -73341.01%Net margin, FY2023: -14710.88%Net margin, FY2024: -644.78%Net margin, FY2025: -101.08%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 -18371.81%. Gross margin FY2022 -37681.29%. Gross margin FY2023 -4798.01%. Gross margin FY2024 98.02%. Gross margin FY2025 99.45%. Operating margin FY2021 -29224.83%. Operating margin FY2022 -72489.21%. Operating margin FY2023 -14264.95%. Operating margin FY2024 -634.20%. Operating margin FY2025 -98.21%. Net margin FY2021 -29448.99%. Net margin FY2022 -73341.01%. Net margin FY2023 -14710.88%. Net margin FY2024 -644.78%. Net margin FY2025 -101.08%.

Income trends

Revenue

49.8M USD+60.24%

Operating income

−48.91M USD+75.19%

Net income

−50.34M USD+74.88%
Income trends across reported periods74.82M USD−25.26M USD−125.34M USD−225.42M USDRevenue, FY2021: 298K USDRevenue, FY2022: 139K USDRevenue, FY2023: 1.2M USDRevenue, FY2024: 31.08M USDRevenue, FY2025: 49.8M USDOperating income, FY2021: −87.09M USDOperating income, FY2022: −100.76M USDOperating income, FY2023: −171.75M USDOperating income, FY2024: −197.12M USDOperating income, FY2025: −48.91M USDNet income, FY2021: −87.76M USDNet income, FY2022: −101.94M USDNet income, FY2023: −177.12M USDNet income, FY2024: −200.4M USDNet income, FY2025: −50.34M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 298K USD. Revenue FY2022 139K USD. Revenue FY2023 1.2M USD. Revenue FY2024 31.08M USD. Revenue FY2025 49.8M USD. Operating income FY2021 −87.09M USD. Operating income FY2022 −100.76M USD. Operating income FY2023 −171.75M USD. Operating income FY2024 −197.12M USD. Operating income FY2025 −48.91M USD. Net income FY2021 −87.76M USD. Net income FY2022 −101.94M USD. Net income FY2023 −177.12M USD. Net income FY2024 −200.4M USD. Net income FY2025 −50.34M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue49.8M USD31.08M USD1.2M USD139K USD298K USD
Cost of goods sold274K USD616K USD58.97M USD52.52M USD55.05M USD
Gross profit49.53M USD30.47M USD−57.77M USD−52.38M USD−54.75M USD
Research and development61.12M USD84.48M USD58.89M USD52.82M USD55.05M USD
Selling, general, and administrative37.32M USD131.9M USD———
Operating expenses98.44M USD227.58M USD113.98M USD48.38M USD32.34M USD
Interest income6.91M USD12.29M USD7.73M USD1.6M USD134K USD
Interest expense8.34M USD15.58M USD13.1M USD2.78M USD802K USD
Depreciation and amortization621K USD534K USD554K USD427K USD292K USD
Operating income−48.91M USD−197.12M USD−171.75M USD−100.76M USD−87.09M USD
Net income−50.34M USD−200.4M USD−177.12M USD−101.94M USD−87.76M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
73%
8 beats, 3 misses, 0 met estimates
Average EPS surprise
+29.28%
11 comparable reports
Latest EPS result
-0.06
Estimate -0.05 · Miss by 19.45%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates0.05-0.02-0.08-0.15Q1 '25BeatQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26MissQ4 '26Estimate
Q1 2025, reported Mar 6, 2025: actual -0.09, estimate -0.11, surprise +18.18%, Beat. Q2 2025, reported May 13, 2025: actual -0.07, estimate -0.1, surprise +30.00%, Beat. Q3 2025, reported Aug 6, 2025: actual 0.01, estimate -0.08, surprise +112.50%, Beat. Q4 2025, reported Nov 6, 2025: actual -0.04, estimate -0.07, surprise +42.86%, Beat. Q1 2026, reported Mar 5, 2026: actual -0.04, estimate -0.07, surprise +42.86%, Beat. Q2 2026, reported May 7, 2026: actual -0.003, estimate -0.04, surprise +93.50%, Beat. Q3 2026, reported Aug 6, 2026: actual -0.06, estimate -0.05, surprise -19.45%, Miss. Q4 2026, reported Nov 5, 2026: actual —, estimate -0.06, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates31.12M20.94M10.77M588.2KQ1 '25BeatQ2 '25MissQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26MissQ4 '26Estimate
Q1 2025, reported Mar 6, 2025: actual 26.55M USD, estimate 2.82M USD, surprise +842.63%, Beat. Q2 2025, reported May 13, 2025: actual 1.26M USD, estimate 1.31M USD, surprise -3.42%, Miss. Q3 2025, reported Aug 6, 2025: actual 28.87M USD, estimate 5.81M USD, surprise +396.71%, Beat. Q4 2025, reported Nov 6, 2025: actual 14.18M USD, estimate 3.14M USD, surprise +351.43%, Beat. Q1 2026, reported Mar 5, 2026: actual 5.49M USD, estimate 3.14M USD, surprise +74.85%, Beat. Q2 2026, reported May 7, 2026: actual 21.1M USD, estimate 9.79M USD, surprise +115.55%, Beat. Q3 2026, reported Aug 6, 2026: actual 692K USD, estimate 3.99M USD, surprise -82.66%, Miss. Q4 2026, reported Nov 5, 2026: actual —, estimate 2.83M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$6.00

160.87% upside
Past 12 months12-month forecastHigh $6.00Average $6.00Low $6.00

LXRX peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding LXRX

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
16.36M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
13.57M
Weight
0.02%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$299.96+0.77%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
6.01M
Weight
0.01%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares Russell 2000 Growth ETF logoiShares Russell 2000 Growth ETFIWO
Market value
4.97M
Weight
0.03%
AUM
15.16B USD
Expense ratio
0.24%
Price / 1D
$387.37+1.24%
Vanguard Russell 2000 ETF logoVanguard Russell 2000 ETFVTWO
Market value
3.22M
Weight
0.02%
AUM
17.4B USD
Expense ratio
0.06%
Price / 1D
$121.25+0.74%
State Street SPDR S&P Pharmaceuticals ETF logoState Street SPDR S&P Pharmaceuticals ETFXPH
Market value
2.99M
Weight
0.53%
AUM
560.87M USD
Expense ratio
0.35%
Price / 1D
$72.80+0.71%
Schwab U.S. Small-Cap ETF logoSchwab U.S. Small-Cap ETFSCHA
Market value
2.38M
Weight
0.01%
AUM
23.1B USD
Expense ratio
0.03%
Price / 1D
$34.83+0.52%
iShares Micro-Cap ETF logoiShares Micro-Cap ETFIWC
Market value
1.87M
Weight
0.12%
AUM
1.53B USD
Expense ratio
0.60%
Price / 1D
$198.39+1.10%

Continue in GoAI

Research LXRX

research.disclaimer